Figure 6.

Simultaneous and not sequential treatment of palbociclib with cytotoxic chemotherapy significantly inhibits disease burden in two Philadelphia chromosome-like B-cell acute lymphoblastic leukemia samples in vivo. Pretreatment with palbociclib (palbo) vs. vehicle (veh) for 7 days by oral gavage, followed by treatment by three common chemotherapy agents: vincristine (VCR, green), L-asparaginase (Asp, blue) or dexamethasone (Dex, red). Concurrent treatment of palbo vs. veh with chemotherapy agents: VCR, Asp or Dex for the duration of the trial of 21 days. Peripheral blood blast count (PBC) over time in two B-cell acute lymphoblastic leukemia (B-ALL) patient-derived xenograft (PDX) (JH561 and NH011). Graphed are means and standard error of PBCx10⁶ per mL on the vertical axis and days of treatment on the X axis. Samples following the pretreatment schema are depicted in the left column, while concurrent treatment is shown in the right column. P-values were calculated using ANOVA to detect the difference between single agent either chemotherapy or CDK inhibitors compared to the combination of both drugs.